- Home
- ELVN vs SABR Comparison
ELVN vs SABR Comparison
Compare ELVN & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- SABR
- Stock Information
- Founded
- ELVN 2016
- SABR 2006
- Country
- ELVN United States
- SABR United States
- Employees
- ELVN N/A
- SABR N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- SABR Computer Software: Programming Data Processing
- Sector
- ELVN Health Care
- SABR Technology
- Exchange
- ELVN Nasdaq
- SABR Nasdaq
- Market Cap
- ELVN 1.2B
- SABR 1.2B
- IPO Year
- ELVN 2020
- SABR 2014
- Fundamental
- Price
- ELVN $20.90
- SABR $1.85
- Analyst Decision
- ELVN Strong Buy
- SABR Buy
- Analyst Count
- ELVN 5
- SABR 5
- Target Price
- ELVN $41.20
- SABR $4.12
- AVG Volume (30 Days)
- ELVN 563.5K
- SABR 4.9M
- Earning Date
- ELVN 11-12-2025
- SABR 10-30-2025
- Dividend Yield
- ELVN N/A
- SABR N/A
- EPS Growth
- ELVN N/A
- SABR N/A
- EPS
- ELVN N/A
- SABR N/A
- Revenue
- ELVN N/A
- SABR $3,010,157,000.00
- Revenue This Year
- ELVN N/A
- SABR N/A
- Revenue Next Year
- ELVN $20.05
- SABR $3.91
- P/E Ratio
- ELVN N/A
- SABR N/A
- Revenue Growth
- ELVN N/A
- SABR 6.13
- 52 Week Low
- ELVN $13.30
- SABR $1.69
- 52 Week High
- ELVN $30.03
- SABR $4.63
- Technical
- Relative Strength Index (RSI)
- ELVN 51.84
- SABR 42.97
- Support Level
- ELVN $19.02
- SABR $1.79
- Resistance Level
- ELVN $20.66
- SABR $1.87
- Average True Range (ATR)
- ELVN 1.00
- SABR 0.06
- MACD
- ELVN 0.09
- SABR 0.02
- Stochastic Oscillator
- ELVN 69.85
- SABR 36.11
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company announced a planned sale of its growing hotel IT solutions division (9% of revenue) to TPG for $960 million in net proceeds, which is scheduled to close in late 2025. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.